432 related articles for article (PubMed ID: 29948756)
1. Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI
Hughey AB; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Ahsan S; Kaatz S; Froehlich JB; Barnes GD
J Thromb Thrombolysis; 2018 Oct; 46(3):316-324. PubMed ID: 29948756
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Alings M; De Caterina R; Eikelboom JW; Ezekowitz MD; Held C; Huber K; Hylek EM; Granger CB; Lopes RD; Vinereanu D; Siegbahn A; Wallentin L
JAMA Netw Open; 2020 Sep; 3(9):e2015943. PubMed ID: 32936298
[TBL] [Abstract][Full Text] [Related]
5. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database.
Lee S; Monz BU; Clemens A; Brueckmann M; Lip GY
BMJ Open; 2012; 2(6):. PubMed ID: 23242482
[TBL] [Abstract][Full Text] [Related]
6. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Deedwania PC; Huang GW
Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
[TBL] [Abstract][Full Text] [Related]
7. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
9. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial.
Guimarães PO; Wojdyla DM; Alexander JH; Thomas L; Alings M; Flaker GC; Al-Khatib SM; Hanna M; Horowitz JD; Wallentin L; Granger CB; Lopes RD
Int J Cardiol; 2017 Jan; 227():443-449. PubMed ID: 27852444
[TBL] [Abstract][Full Text] [Related]
11. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
[TBL] [Abstract][Full Text] [Related]
12. Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.
Biteker M; Başaran Ö; Doğan V; Altun İ; Özpamuk Karadeniz F; Tekkesin Aİ; Çakıllı Y; Türkkan C; Hamidi M; Demir V; Gürsoy MO; Tek Öztürk M; Aksan G; Seyis S; Ballı M; Alıcı MH; Bozyel S
J Am Geriatr Soc; 2017 Aug; 65(8):1684-1690. PubMed ID: 28394435
[TBL] [Abstract][Full Text] [Related]
13. Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI(2)).
Barnes GD; Kaatz S; Winfield J; Gu X; Haymart B; Kline-Rogers E; Kozlowski J; Beasley D; Almany S; Leyden T; Froehlich JB
J Thromb Thrombolysis; 2014; 37(2):171-6. PubMed ID: 23653172
[TBL] [Abstract][Full Text] [Related]
14. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Lip GY; Lane DA
Am J Med; 2010 Sep; 123(9):785-9. PubMed ID: 20655037
[TBL] [Abstract][Full Text] [Related]
15. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation.
Jia B; Lynn HS; Rong F; Zhang W
J Cardiovasc Pharmacol; 2014 Oct; 64(4):368-74. PubMed ID: 24869601
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
18. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Hess CN; Al-Khatib SM; Granger CB; Lopes R
Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
[TBL] [Abstract][Full Text] [Related]
19. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
[TBL] [Abstract][Full Text] [Related]
20. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Rost NS; Giugliano RP; Ruff CT; Murphy SA; Crompton AE; Norden AD; Silverman S; Singhal AB; Nicolau JC; SomaRaju B; Mercuri MF; Antman EM; Braunwald E;
Stroke; 2016 Aug; 47(8):2075-82. PubMed ID: 27387994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]